文献速递泌尿生殖骨肌技术与安全MRPET

全身MRI评估多发性转移性激素敏感性前列腺癌初始系统治疗后的残留肿瘤负荷

Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer.
PubMed 文献 · Br J Radiol · 2026-01-01

该可行性研究纳入29例多发性转移(>5处)激素敏感性前列腺癌患者,在ARPI或多西他赛初始系统治疗后中位5.5个月行全身MRI,按MET-RADS-P标准评估。20/29(69.0%)患者被降危为寡转移(≤5处),降危者中位PSA为0.2 ng/mL,未降危者为1.5 ng/mL,55%(11/20)降危者仍有残留前列腺内病变。全身MRI与PSA反应相关,支持诱导性寡转移状态的存在。

要点

  • 全身MRI可按MET-RADS-P标准评估多发性转移性激素敏感性前列腺癌系统治疗后的残留肿瘤负荷。
  • 系统治疗后约69%患者可降危为寡转移(≤5处),需关注残留前列腺内病变(55%)。
  • 全身MRI与PSA反应相关,可作为潜在影像生物标志物,但样本量小需进一步验证。
英文原文(摘要)· 点击展开

OBJECTIVES: Treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded, with evidence supporting prostate radiotherapy in low-volume disease. However, evidence for consolidative radiotherapy to residual sites in patients rendered oligometastatic after systemic therapy is lacking. Advanced imaging with WB-MRI and PSMA PET/CT enables more accurate assessment of tumor burden and response.

METHODS: This feasibility study assessed response to initial systemic treatment with an ARPI or docetaxel in 29 patients with polymetastatic (>5 metastases) HSPC. PSA and WB-MRI response using MET-RADS-P criteria were recorded.

RESULTS: A total of 20/29 (69.0.%) of patients were down-risked to oligometastatic disease (≤5 sites) after a median of 5.5 (IQR 5-5.8) months, identified on WB-MRI. Median PSA was 0.2 ng/mL (IQR 0.1-0.7) in down-risked patients vs 1.5 ng/mL (IQR 1.1-84) in those not down-risked. Residual intraprostatic disease was seen in 55% (11/20) of down-risked patients.

CONCLUSIONS: Most patients were down-risked on WB-MRI, supporting the existence of an induced oligometastatic state and providing rationale for the STAR TRAP randomized trial (ISRCTN16448082), which will assess the role of consolidative radiotherapy in this setting.

ADVANCES IN KNOWLEDGE: WB-MRI correlates with PSA response and shows potential as an imaging biomarker in mHSPC in this small feasibility study.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Thompson C, Withey SJ, Tunariu N, et al. Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. Br J Radiol. 2026. PMID: 42517815. doi:10.1093/bjr/tqag168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。